Investor Alert: Robbins LLP Informs Investors of the EyePoint, Inc. Class Action Lawsuit
EyePoint PharmaceuticalsEyePoint Pharmaceuticals(US:EYPT) Businesswire·2026-11-18 15:23

文章核心观点 - EyePoint公司被指控在DURAVYU治疗湿性年龄相关性黄斑变性的疗效和可行性方面误导投资者 [1] 公司相关 - EyePoint(股票代码EYPT)面临有关DURAVYU产品疗效及可行性方面的投资者误导指控 [1] - 争议焦点集中于DURAVYU用于治疗湿性年龄相关性黄斑变性的效果与可行性 [1] 行业相关 - 湿性年龄相关性黄斑变性治疗领域出现产品疗效与可行性争议事件 [1]

EyePoint Pharmaceuticals-Investor Alert: Robbins LLP Informs Investors of the EyePoint, Inc. Class Action Lawsuit - Reportify